ES2534318B1 - Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck - Google Patents
Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck Download PDFInfo
- Publication number
- ES2534318B1 ES2534318B1 ES201331542A ES201331542A ES2534318B1 ES 2534318 B1 ES2534318 B1 ES 2534318B1 ES 201331542 A ES201331542 A ES 201331542A ES 201331542 A ES201331542 A ES 201331542A ES 2534318 B1 ES2534318 B1 ES 2534318B1
- Authority
- ES
- Spain
- Prior art keywords
- mixture
- compound
- ethyl acetate
- organic layer
- synthesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003993 interaction Effects 0.000 title abstract description 9
- 150000004703 alkoxides Chemical group 0.000 title abstract 2
- 150000008371 chromenes Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract description 30
- 238000006243 chemical reaction Methods 0.000 abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 13
- 238000011282 treatment Methods 0.000 abstract description 4
- 206010052779 Transplant rejections Diseases 0.000 abstract description 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 2
- 208000026278 immune system disease Diseases 0.000 abstract description 2
- 208000027866 inflammatory disease Diseases 0.000 abstract description 2
- 230000002062 proliferating effect Effects 0.000 abstract description 2
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical group C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 87
- 239000000203 mixture Substances 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 34
- 230000015572 biosynthetic process Effects 0.000 description 31
- 239000012044 organic layer Substances 0.000 description 28
- 238000003786 synthesis reaction Methods 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 239000000047 product Substances 0.000 description 22
- 238000000746 purification Methods 0.000 description 22
- 239000012043 crude product Substances 0.000 description 21
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- 235000015320 potassium carbonate Nutrition 0.000 description 17
- 229910000027 potassium carbonate Inorganic materials 0.000 description 17
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 13
- 239000012453 solvate Substances 0.000 description 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 8
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical group CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- -1 (6- (cyclopropylmethoxy) -4- (4-fluorophenyl) -2H-chromen-3-yl) methyl Chemical group 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- DDFYFBUWEBINLX-UHFFFAOYSA-M tetramethylammonium bromide Chemical compound [Br-].C[N+](C)(C)C DDFYFBUWEBINLX-UHFFFAOYSA-M 0.000 description 2
- QBXYUIIBKHOJFA-UHFFFAOYSA-N (2,2,4-trimethyl-1h-quinolin-6-yl) 2-(4-fluorophenyl)acetate Chemical compound C1=C2C(C)=CC(C)(C)NC2=CC=C1OC(=O)CC1=CC=C(F)C=C1 QBXYUIIBKHOJFA-UHFFFAOYSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FYNMAPJTGKYTHR-UHFFFAOYSA-N 1-bromo-1-methylcyclopropane Chemical compound CC1(Br)CC1 FYNMAPJTGKYTHR-UHFFFAOYSA-N 0.000 description 1
- UPMBBVHNRHGNOX-UHFFFAOYSA-N 2-fluoro-n-[(4-phenyloxan-4-yl)methyl]benzamide Chemical compound FC1=CC=CC=C1C(=O)NCC1(C=2C=CC=CC=2)CCOCC1 UPMBBVHNRHGNOX-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- MOOAHMCRPCTRLV-UHFFFAOYSA-N boron sodium Chemical compound [B].[Na] MOOAHMCRPCTRLV-UHFFFAOYSA-N 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201331542A ES2534318B1 (es) | 2013-10-18 | 2013-10-18 | Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck |
| CN201480057192.8A CN105658634B (zh) | 2013-10-18 | 2014-10-20 | 作为TCR-Nck相互作用的抑制剂的被醇盐取代的色烯衍生物 |
| EP14809703.3A EP3059232B1 (en) | 2013-10-18 | 2014-10-20 | Chromene derivatives substituted by alkoxide as inhibitors of the tcr-nck interaction |
| RU2016118037A RU2658910C2 (ru) | 2013-10-18 | 2014-10-20 | Производные хромена, замещённые посредством алкоксида, в качестве ингибиторов взаимодействия tcr-nck |
| AU2014335859A AU2014335859B2 (en) | 2013-10-18 | 2014-10-20 | Chromene derivatives substituted by alkoxide as inhibitors of the TCR-Nck interaction |
| JP2016522733A JP6505095B2 (ja) | 2013-10-18 | 2014-10-20 | Ｔｃｒ−ｎｃｋ相互作用の阻害剤としての、アルコキシドによって置換されたクロメン誘導体 |
| PCT/IB2014/002171 WO2015056085A1 (es) | 2013-10-18 | 2014-10-20 | Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción tcr-nck |
| ES14809703T ES2719115T3 (es) | 2013-10-18 | 2014-10-20 | Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck |
| CA2925846A CA2925846C (en) | 2013-10-18 | 2014-10-20 | Chromene derivatives substituted by alkoxide as inhibitors of the tcr-nck interaction |
| US15/029,042 US10131647B2 (en) | 2013-10-18 | 2014-10-20 | Chromene derivatives substituted by alkoxide as inhibitors of the TCR-Nck interaction |
| HK16114566A HK1226388A1 (zh) | 2013-10-18 | 2016-12-22 | 作為tcr-nck相互作用的抑制劑的被醇鹽取代的色烯衍生物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201331542A ES2534318B1 (es) | 2013-10-18 | 2013-10-18 | Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2534318A1 ES2534318A1 (es) | 2015-04-21 |
| ES2534318B1 true ES2534318B1 (es) | 2016-01-28 |
Family
ID=52016805
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES201331542A Active ES2534318B1 (es) | 2013-10-18 | 2013-10-18 | Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck |
| ES14809703T Active ES2719115T3 (es) | 2013-10-18 | 2014-10-20 | Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14809703T Active ES2719115T3 (es) | 2013-10-18 | 2014-10-20 | Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10131647B2 (zh) |
| EP (1) | EP3059232B1 (zh) |
| JP (1) | JP6505095B2 (zh) |
| CN (1) | CN105658634B (zh) |
| AU (1) | AU2014335859B2 (zh) |
| CA (1) | CA2925846C (zh) |
| ES (2) | ES2534318B1 (zh) |
| HK (1) | HK1226388A1 (zh) |
| RU (1) | RU2658910C2 (zh) |
| WO (1) | WO2015056085A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2534336B1 (es) * | 2013-10-18 | 2016-01-28 | Artax Biopharma Inc. | Derivados de cromeno como inhibidores de la interacción TCR-Nck |
| EA037785B1 (ru) | 2016-04-12 | 2021-05-21 | Джапан Тобакко Инк. | Ароматический ингалятор |
| SG11202008067QA (en) * | 2018-02-27 | 2020-09-29 | Artax Biopharma Inc | Chromene derivatives as inhibitors of tcr-nck interaction |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA62993C2 (en) * | 1997-12-19 | 2004-01-15 | Bayer Ag | CHROMAN DERIVATIVES SUBSTITUTED ON CARBOXYLIC GROUP USED AS AGONISTS OF b-3-ADRENORECEPTOR |
| DE19858341A1 (de) * | 1998-12-17 | 2000-06-21 | Merck Patent Gmbh | Chromanderivate |
| EP1230232B1 (en) | 1999-11-05 | 2004-02-25 | Cytovia, Inc. | Substituted 4h-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| AU2001278980A1 (en) | 2000-07-21 | 2002-02-05 | Chugai Seiyaku Kabushiki Kaisha | Coumarin derivatives useful as tnfalpha inhibitors |
| EP1392283A4 (en) | 2001-05-16 | 2004-10-20 | Cytovia Inc | COUMARINS AND SUBSTITUTED QUINOLINES USED AS CASPASE ACTIVATORS |
| WO2003062272A1 (es) | 2002-01-24 | 2003-07-31 | Consejo Superior De Investigaciones Científicas | Nueva estrategia moduladora de la activacion de los linfocitos t basada en la regulación de la interaccion cd3e- nck. |
| WO2003096982A2 (en) | 2002-05-16 | 2003-11-27 | Cytovia, Inc. | Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| GB0607389D0 (en) | 2006-04-12 | 2006-05-24 | Novartis Ag | Organic compounds |
| ES2331451B1 (es) | 2008-06-30 | 2010-10-21 | Consejo Superior De Investigaciones Cientificas (Csic) | Inmunosupresor basado en la interrupcion de la interaccion tcr-nck. |
| JP2011528359A (ja) | 2008-07-16 | 2011-11-17 | ブリストル−マイヤーズ スクイブ カンパニー | ケモカイン受容体活性のクロメンモジュレーター |
| RU2490266C2 (ru) * | 2008-12-05 | 2013-08-20 | Астеллас Фарма Инк. | Соединение 2н-хромена и его производное |
| ES2379242B1 (es) | 2010-09-28 | 2013-03-04 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados de cromeno. |
| ES2534336B1 (es) | 2013-10-18 | 2016-01-28 | Artax Biopharma Inc. | Derivados de cromeno como inhibidores de la interacción TCR-Nck |
-
2013
- 2013-10-18 ES ES201331542A patent/ES2534318B1/es active Active
-
2014
- 2014-10-20 JP JP2016522733A patent/JP6505095B2/ja active Active
- 2014-10-20 WO PCT/IB2014/002171 patent/WO2015056085A1/es active Application Filing
- 2014-10-20 ES ES14809703T patent/ES2719115T3/es active Active
- 2014-10-20 CA CA2925846A patent/CA2925846C/en active Active
- 2014-10-20 CN CN201480057192.8A patent/CN105658634B/zh active Active
- 2014-10-20 RU RU2016118037A patent/RU2658910C2/ru active
- 2014-10-20 US US15/029,042 patent/US10131647B2/en active Active
- 2014-10-20 AU AU2014335859A patent/AU2014335859B2/en active Active
- 2014-10-20 EP EP14809703.3A patent/EP3059232B1/en active Active
-
2016
- 2016-12-22 HK HK16114566A patent/HK1226388A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10131647B2 (en) | 2018-11-20 |
| AU2014335859B2 (en) | 2018-11-01 |
| ES2534318A1 (es) | 2015-04-21 |
| CA2925846A1 (en) | 2015-04-23 |
| CN105658634B (zh) | 2019-01-22 |
| CA2925846C (en) | 2019-02-19 |
| HK1226388A1 (zh) | 2017-09-29 |
| US20160244423A1 (en) | 2016-08-25 |
| JP6505095B2 (ja) | 2019-04-24 |
| CN105658634A (zh) | 2016-06-08 |
| WO2015056085A1 (es) | 2015-04-23 |
| ES2719115T3 (es) | 2019-07-08 |
| JP2017506209A (ja) | 2017-03-02 |
| RU2016118037A (ru) | 2017-11-23 |
| AU2014335859A1 (en) | 2016-05-05 |
| EP3059232A1 (en) | 2016-08-24 |
| EP3059232B1 (en) | 2019-01-09 |
| RU2658910C2 (ru) | 2018-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2635564T3 (es) | Profármaco de tenofovir y usos farmacéuticos del mismo | |
| ES2729498T3 (es) | Derivados del ácido piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| ES2456640T3 (es) | Forma cristalina del hemihidrato de 1-(beta-D-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno | |
| CA3084694A1 (en) | Sulphonyl urea derivatives as nlrp3 inflammasome modulators | |
| ES2701098T7 (es) | Derivados de acilaminopirimidina para el tratamiento de infecciones víricas y otras enfermedades | |
| CA3214676A1 (en) | Pyridazine compounds for inhibiting nlrp3 | |
| KR20190026827A (ko) | 방향족 아세틸렌 또는 방향족 에틸렌계 화합물, 그의 중간체, 제조 방법, 약물 조성물 및 용도 | |
| ES2927346T3 (es) | Inhibidores de HPK1, método de preparación y aplicación de los mismos | |
| KR20200086385A (ko) | 캡 의존성 엔도뉴클레아제 억제제 | |
| ES2653522T3 (es) | Un novedoso compuesto de triazolo-piridina | |
| AU2016382372B2 (en) | Sulfonamide derivative and preparation method and use thereof | |
| ES2534318B1 (es) | Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck | |
| EP4074699A1 (en) | Compound as cyclin-dependent kinase 9 inhibitor and use thereof | |
| ES2699884T3 (es) | Nuevo compuesto cristalino de arilalquilamina y método para producir el mismo | |
| ES2379242B1 (es) | Derivados de cromeno. | |
| WO2022006433A1 (en) | Compounds, compositions and methods | |
| CA3024918A1 (en) | Mitochondrial inhibitors for the treatment of proliferation disorders | |
| Desideri et al. | Synthesis and evaluation of anti-rhinovirus 1B activity of oxazolinyl-isoflavans and-3 (2H)-isoflavenes | |
| ES2670802T3 (es) | Forma cristalina de abacavir que está esencialmente libre de disolvente | |
| ES2869023T3 (es) | Derivados de cromeno como inhibidores de la interacción TCR-Nck | |
| CA3190686A1 (en) | Heterocyclic compound as bcl-2 inhibitor | |
| CN116102533A (zh) | 一种芳杂环类化合物及其应用 | |
| RU2819762C1 (ru) | Соединение в качестве ингибитора циклинзависимой киназы 9 и его применение | |
| RU2806033C2 (ru) | Ингибиторы, способ их получения и применение | |
| RU2782469C2 (ru) | Апоптоз-индуцирующие агенты |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 2534318 Country of ref document: ES Kind code of ref document: B1 Effective date: 20160128 |